NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,019.9 mln
Float55.69 mln
Earnings Date08/04/2026
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-2.98
Likely reliable
1-Year Forecast
138
Exceptional upside
Relative Strength
17
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-92.13
Deeply negative
Business Description
Rhythm Pharmaceuticals is a Boston-based drug company focused on developing treatments for rare hormonal disorders that cause severe obesity. Its primary approved medicine, IMCIVREE, targets a specific receptor in the brain that regulates body weight and is used to treat several genetic conditions linked to abnormal weight gain. The company is running multiple clinical trials to expand the use of IMCIVREE and to test two additional drug candidates that work through the same biological pathway. Founded in 2008, Rhythm serves patients across the United States and in other countries around the world.
